Key Highlights

  • The company said it had completed fully automated sequencing runs on integrated Proteus instruments, its next-generation platform, using a developmental kit that reads 17 of the 20 amino acids.
  • The figures below cover the first quarter of 2026, reported on 7 May, and the year.
  • The striking feature at this price is the arithmetic. A market capitalisation near US$157m sits below the US$190.4m of cash and investments reported.
  • The deadline is real and the shares sit 28% below the threshold.

Why the market is paying attention

The first is technical. The company said it had completed fully automated sequencing runs on integrated Proteus instruments, its next-generation platform, using a developmental kit that reads 17 of the 20 amino acids. Commercial launch is targeted for the end of 2026.

The second is financial. Quantum-Si (NASDAQ:QSI) disclosed a Nasdaq notice confirming its Class A shares had closed below US$1.00 for 30 consecutive business days, breaching the minimum bid price rule. It has to record ten consecutive closes at or above a dollar.

That values the business near US$157m, less than the US$190.4m of cash and investments held at the end of March.

What the company does

Genomics reads DNA. Proteomics reads the proteins DNA codes for, and proteins are where most drug targets and most disease biology sit. The dominant tool is mass spectrometry: powerful, but expensive, specialist-heavy and weak on low-abundance samples.

Quantum-Si, based in Branford, Connecticut, sells an alternative, single-molecule protein sequencing on a benchtop instrument. Its commercial product today is the Platinum Pro system; its future rests on Proteus, which swaps Platinum's semiconductor detection for an optical approach built around the KinetIQ Array. The model is the razor-and-blade of life-science tools: instruments go to laboratories and biopharmaceutical groups, and recurring revenue is meant to come from consumable kits and service.

Positioning has been deliberate: rather than attacking Orbitrap-class mass spectrometers or high-plex affinity platforms head-on, management presents Proteus as a complementary tool for post-translational modifications and protein variants in low-abundance samples.

Latest financial and operating performance

The figures below cover the first quarter of 2026, reported on 7 May, and the year.

Q1 2026 revenue was US$258,000, down 69% from US$842,000 a year earlier, US$216,000 of product and US$42,000 of service. Gross profit was US$74,000, a 29% margin against 58% a year before. Full-year 2025 revenue was US$2.4m at a 47% margin.

Costs dwarf sales. Q1 operating expenses were US$24.1m, research and development US$14.5m, selling and administrative US$9.6m, for an operating loss of US$24.1m. The net loss was US$21.7m, or US$0.10 per diluted share. FY2025 brought a US$101.3m net loss.

Cash, equivalents and marketable securities stood at US$190.4m, down from US$215.8m three months earlier. There is no conventional debt; the accumulated deficit has reached US$719.7m. Management guides to a runway into the second quarter of 2028.

Guidance for 2026 points down: revenue of approximately US$1.0m, adjusted operating expenses of US$98.0m or less, cash usage of US$93.0m or less. The company attributes the decline to Proteus upgrade credits embedded in Platinum Pro units sold this year, and to customers postponing purchases.

The catalyst that matters: a launch year with a deadline attached

The Proteus launch is not simply a product event; it is the moment the capital structure starts earning its keep. The US$117m spent in 2025 and the US$98m budgeted for 2026 are a bet that a commercial instrument arrives, is bought, and pulls consumable revenue behind it.

That makes the run of 2026 announcements matter more than any single one. Automated runs on integrated instruments in April removed an engineering risk. The kit moving from 15 amino acids at its December 2025 release to 17 in development narrows the gap to full coverage. The 10 June collaboration with Cell Signaling Technology, benchmarking Proteus against mass spectrometry data, aims to reach launch with third-party validation.

The Nasdaq notice changes the calculus. Non-compliance does not affect operations, but it constrains the cheapest source of future funding: raising equity at 72 cents is dilutive, and raising it under a listing deficiency is worse.

The bull case

The striking feature at this price is the arithmetic. A market capitalisation near US$157m sits below the US$190.4m of cash and investments reported. On a strict reading, the market is assigning no value to the technology or the Proteus programme.

If Proteus launches on time and finds buyers, that changes quickly. Instruments in this class have been discussed at price points in the hundreds of thousands of dollars, so even modest placements move a company guiding to US$1.0m of revenue.

Independent validation is accumulating. An April 2026 bioRxiv preprint from University of British Columbia and B.C. Cancer Research Institute researchers used the technology to study cohesin complexes, work with implications for genome instability in tumours.

The bear case and the risks

Listing compliance. The deadline is real and the shares sit 28% below the threshold. The fallbacks, a transfer to the Nasdaq Capital Market for a second 180-day period, or a reverse split, fix the arithmetic without fixing the business.

Revenue has gone backwards. Q1 2026 revenue of US$258,000 followed US$451,000 in Q4 2025 and US$552,000 in Q3 2025. The explanation that customers are waiting for Proteus is plausible but unfalsifiable until Proteus ships. If deferred demand does not convert, this becomes a demand problem rather than a timing one.

Launch execution. The developmental kit reads 17 of 20 amino acids. Late-stage launches routinely slip, and a delay past end-2026 would push meaningful revenue into 2028 while the burn continues near US$90m a year.

Funding and competition. The Q1 filing lists future capital needs among its risks, alongside better-capitalised rivals, supply chain disruption and tariffs. A 29% gross margin on sub-US$300,000 of quarterly revenue leaves no self-funding cushion.

What investors should watch next

, second-quarter results. The first hard checkpoint: whether early-access Proteus sites are live, the cash balance against the US$93m usage cap, and whether the US$1.0m revenue guidance holds.

Amino acid coverage. Progress from 17 towards 20 in the shipping configuration is the clearest measure of launch readiness.

The share price to. Ten consecutive closes at or above US$1.00 resolves the deficiency; an 8-K announcing a market transfer or reverse split is the alternative path.

Placements and partnership output. Whether an installed base figure is published at launch, and whether the Cell Signaling Technology work yields published data.

Investor takeaway

Quantum-Si is a binary-feeling situation dressed as a tools company. The verified position as : quarterly revenue of US$258,000, cash burn guided to US$93m or less this year, US$190.4m of cash and investments at the end of March, and a Nasdaq bid-price deficiency running to.

Against that, the Proteus programme has hit the milestones management set out, and the market is valuing the company below its own net cash, either a mispricing or a fair discount for the burn rate, depending on whether the launch lands.

Nothing here is settled. The 13 August results and the end-2026 launch window will resolve more than any commentary in between.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.